Thromboembolic Events in Severe COVID-19 Patients

University Hospital, Strasbourg, France300 enrolled

Overview

The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Pulmonary Thromboembolism

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed infection with the Sars-CoV-2 virus (RT-PCR) * Hospitalization in Intensive Care Unit * Age over 18 years Old Exclusion Criteria: * Refusal of the patient to participate in data collection

Locations (1)

Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Analysis of incidence of thromboembolic events in patients with Sars-CoV-2

Time frame: 1 month

Central Contacts

Charles TACQUARD, MD

CONTACT

33 3 69 55 16 08 charlesambroise.tacquard@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90 said.chayer@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.